Menu

Novel Cystic Fibrosis Drug Approved

After a lightning-fast approval, the first medicine to treat an underlying cause of the disorder hits the market.

Feb 1, 2012
Megan Scudellari

The US Food and Drug Administration has approved the first drug to treat a genetic cause of cystic fibrosis (CF), the agency announced yesterday (January 31). The drug, Vertex’s Kalydeco, was granted approval in approximately 3 months, twice as fast as normal FDA priority reviews and one of the fastest FDA approvals ever, according to a Vertex press release. It is one of the first drugs approved to correct a specific genetic defect.

CF, the most common fatal genetic disease in the Caucasian population, is caused by defective or missing CFTR proteins, cell receptors that regulate ion and water transport in and out of cells. Lack of CFTR proteins results in the buildup of a thick, sticky mucus in the lungs. Kalydeco, a twice-a-day pill, is approved for use in people with the G551D mutation in the CFTR gene. Approximately 1,200 people in the United States, or 4 percent of those with CF, have the G551D mutation.

"Kalydeco is an excellent example of the promise of personalized medicine—targeted drugs that treat patients with a specific genetic makeup," FDA Commissioner Margaret Hamburg said in an FDA press release.

“Even though this drug isn’t for the majority of people, it proves that you can look at the mistake in the genes and design a drug in a rational way that will fix the problem,” Drucy Borowitz, director of the cystic fibrosis program at the State University of New York at Buffalo, told the Associated Press.

In two phase III trials involving 213 patients with the G551D mutation, the drug resulted in significant and sustained improvements in lung function. It is not effective in patients with other CFTR mutations, including F508, the most common CFTR mutation that results in CF.

Kalydeco, which begins shipping to pharmacies this week, will cost patients $294,000 per year, reported FierceBiotech, which is typical for a drug targeting a small disease population such as this. Vertex will provide Kalydeco for free to those who do not have insurance and have an annual household income of $150,000 or less, the company said.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.